Findings
========

Mitochondrial dysfunction is a well-described complication of anti-retroviral therapy \[[@B1]-[@B7]\]. It is most strongly associated with several of the older nucleoside analogue reverse transcriptase inhibitors (NRTIs): zidovudine (AZT), stavudine (d4T), didanosine (ddI), and zalcitabine (ddC). Although these drugs are no longer in common usage in industrialised countries, there are nevertheless large numbers of patients who have had extensive prior exposure to these drugs, and some remain in common usage in developing countries. We have recently demonstrated that patients with previous exposure to these NRTIs may have persistent cellular mitochondrial COX (cytochrome *c* oxidase) defects in skeletal muscle, consequent on an NRTI-induced accumulation of somatic (acquired) mitochondrial DNA (mtDNA) mutations \[[@B8]\].

Non-invasive measures of mitochondrial damage would be very valuable in the HIV clinic, both for the diagnosis of anti-retroviral associated mitochondrial dysfunction and the serial monitoring of such patients. The determination of mtDNA content in peripheral blood mononuclear cells (PBMCs) has previously been proposed as such a measure \[[@B5],[@B9]-[@B11]\]. This consideration arises from the fact that the mitochondrially-toxic NRTIs (as listed above) cause a reduction in cellular mtDNA content (depletion) during therapy \[[@B2],[@B3],[@B6],[@B10],[@B12]-[@B16]\]. However, modern N(t)RTIs such as tenofovir (TDF) and abacavir (ABC) do not cause mtDNA depletion \[[@B17]\], and as a result, mtDNA levels return to normal with a switch away from a mitochondrially-toxic NRTI. Thus, measuring mtDNA levels is not a useful measure of on-going mitochondrial dysfunction due to an NRTI exposure in the distant past.

In contrast, FGF-21 (fibroblast growth factor 21) has recently been proposed as a valuable serum measure in inherited mitochondrial disease \[[@B18]\]. In these patients, serum FGF-21 levels showed a very strong correlation with mitochondrial dysfunction on skeletal muscle biopsy, as determined by the percentage of cells expressing a COX defect \[[@B18]\]. FGF-21 is thought to regulate mitochondrial activity and enhance oxidative capacity, mediated via PGC-1α (peroxisome proliferator-activated receptor gamma co-activator 1-alpha) expression \[[@B19]\]. To date, one study has assessed serum FGF-21 in HIV infection, and demonstrated elevated levels \[[@B20]\]. Given the recently described association between serum FGF-21 elevation and muscle COX defects in inherited mitochondrial disorders \[[@B18]\], and the recent observation of significant COX defects in long-term anti-retroviral treated HIV-infected patients \[[@B8]\], we speculated that muscle mitochondrial dysfunction might also drive the FGF-21 elevation in anti-retroviral treated HIV infection.

Patient characteristics
-----------------------

All subjects gave informed written consent for participation, and the study was approved by local research ethics committee (Newcastle and North Tyneside Research Ethics Committee). We performed a cross-sectional study of adult HIV-1 infected patients, receiving ambulatory care at one of two specialist clinics in Newcastle-upon-Tyne, UK. Patients with current active hepatitis B or C co-infection, known inherited or non-HIV-associated neuromuscular disease, and diabetes mellitus were excluded. No subjects were clinically obese (BMI \>30). 32 HIV-infected subjects participated, of whom 81% were male. 84% were of white Caucasian ethnicity and the remainder black African. Mean age was 48.7 years, with age range of 29--71 years. Mean duration of diagnosed HIV infection was 10.8 years. Mean current CD4 lymphocyte count was 663 cells/μl, and 61% of subjects had nadir CD4 count of \<200 cells/μl. All subjects were currently receiving combination anti-retroviral therapy, with a mean duration of treatment of 9.2 years. 97% of patients had fully suppressed HIV plasma viral load (\<50 HIV-1 RNA copies/ml). 81% of subjects were receiving a non-nucleoside reverse transcriptase inhibitor (NNRTI) and 22% a ritonavir-boosted protease inhibitor (PI). Regarding past (lifetime) NRTI treatment experience, 72% of patients had a history of AZT exposure, and 25% had a history of prior d-drug (dideoxynucleoside analogue) exposure. Characteristics of individual subjects are shown in Table [1](#T1){ref-type="table"}.

###### 

Patient characteristics

   **Age (y)**   **Gender**   **Ethnicity**   **Duration of diagnosed HIV (mo)**   **ART duration (mo)**   **Nadir CD4 count (cells/uL)**   **Current CD4 count (cells/uL)**   **LDS**   **ART (current)**                       **ART (lifetime)**                        **COX defect (%)**   **Serum FGF-21 (pg/mL)**
  ------------- ------------ --------------- ------------------------------------ ----------------------- -------------------------------- ---------------------------------- --------- ------------------- ------------------------------------------------------------- -------------------- --------------------------
       71            M             WB                        130                            130                          UK                               530                     Y         TDF FTC EFV                        ddi AZT 3TC EFV TDF FTC                            3.0%                    232
       48            F             BA                        100                            99                           10                               487                     N         TDF FTC NVP                        AZT 3TC EFVTDF FTC NVP                             0.1%                   \>1920
       34            F             WB                         88                            86                          218                               1121                    Y         ABC 3TC NVP                            AZT 3TC NVP ABC                                0.0%                    560
       55            F             BA                         64                            27                          112                               426                     N      TDF FTC AZT DRV/r                     TDF FTC LPV/r AZT DRV/r                            0.8%                    164
       43            M             BA                         87                            87                          152                               306                     N         TDF FTC EFV                          AZT 3TC EFV TDF FTC                              0.8%                     20
       42            M             WB                        185                            147                         150                               636                     N         AZT 3TC EFV                              AZT 3TC NVP                                  0.0%                    342
       63            M             WB                         97                            97                          169                               870                     N         ABC 3TC EFV                            AZT 3TC EFV ABC                                0.0%                    204
       29            M             WB                         84                            32                          197                               401                     N         TDF FTC EFV                              TDF FTC EFV                                  0.0%                    809
       63            M             WB                        238                            221                          NA                               438                     N         ABC 3TC NVP                    AZT ddl d4T 3TC ddC IDV NVP ABC                        2.2%                    440
       62            M             WB                         63                            62                           56                               190                     N         TDF FTC NVP                              TOP FTC NVP                                  0.2%                    156
       52            M             WB                        225                            225                         120                               728                    *Y*       TDF FTC ATV/r     AZT ddC ddl 3TC d4T SQV NVP IDV NFV ABC TDF LPV/r FTC ATV/r          1.3%                    328
       36            M             WB                        139                            138                         197                               627                     N         AZT 3TC EFV                          AZT 3TC EFV TDF FTC                              0.3%                    214
       51            M             WB                        190                            183                          10                               747                     N         ABC TDF NVP             AZT ddl d4T 3TC RTV NVP IDV ddC ABC ATV/r TDF                 4.9%                    252
       33            F             WB                         96                            95                           83                               1289                    N         TDF FTC EFV                          AZT 3TC EFV TDF FTC                              0.0%                    177
       48            M             WB                        102                            100                         259                               1329                    Y         AZT 3TC EFV                              AZT 3TC EFV                                  0.4%                    409
       51            M             WB                       *145*                           144                         151                               421                     N         AZT 3TC NVP                              AZT 3TC NVP                                  1.4%                    254
       66            M             WB                         71                            26                          287                               455                     N         TDF FTC EFV                              TDF FTC EFV                                 11.2%                    470
       46            M             WB                        158                            157                         250                               1452                    N         TDF FTC EFV                      AZT 3TC IDV EFV ABC TDF FTC                          1.4%                    1218
       61            M             WB                        116                            113                          NA                               498                     Y         TDF FTC NVP                        AZT 3TC EFV NVP TDF FTC                            2.4%                    182-
       30            M             WB                         88                            23                          283                               661                     N        TDF FTC DRV/r                          TDF FTC EFV DRV/r                               0.1%                    207
       62            M             WB                        284                            202                          NA                               422                     N        ABC NVP LPV/r            SQV AZT ddC 3TC d4T ddl IDV ABC NVP NFV LPV/r                 0.8%                     92
       45                          WB                        159                            158                         176                               660                     N         TDF FTC NVP                        AZT 3TC IDV NVP TDF FTC                            0.0%                     60
       54            M             WB                         79                            38                          244                               638                     N        TDF FTC DRV/r                          TDF FTC EFV DRV/r                               3.4%                    178
       52            M             WB                        166                            164                          0                                662                     Y         TDF FTC NVP                AZT d4T IDV NFV SQV 3TC NVP ddl TDF FTC                    2.8%                    525
       51            M             WB                        243                            171                         327                               539                     Y         TDF FTC EFV                      AZT ddl RTV NFV TDF FTC EFV                          1.5%                    231
       35            F             BA                         62                            25                          380                               638                     N         TDF FTC EFV                              TOP FTC EFV                                  0.0%                     82
       53            M             WB                         NA                            48                          301                               804                     N         TDF FTC EFV                              TDF FTC EFV                                   NA                     490
       36            M             WB                        130                            130                          18                               898                     N        TDF FTC ATV/r                      AZT 3TC EFV TDF FTC ATV/r                           0.0%                    530
       48            M             WB                         53                            14                          332                               443                     N         TDF FTC EFV                              TDF FTC EFV                                  0.0%                     56
       52            F             BA                         83                            81                           17                               485                     Y         TDF FTC EFV                          AZT 3TC EFV TDF FTC                              0.7%                    224
       38            M             WB                        129                            128                          4                                761                     Y         TDF FTC EFV                          AZT 3TC EFV TDF FTC                              0.0%                    935
       47            M             WB                        183                            164                         305                               668                     Y        ABC RAL ATV/r                  d4T 3TC NVP ddl IDV ABC ATV/r RAL                       9.8%                    114

Summary characteristics of individual HIV-infected subjects. (WB, white British; BA, black African; ART, anti-retroviral therapy; LDS, lipodystrophy syndrome; AZT, zidovudine; d4T, stavudine; ddI, didanosine; ddC, zalcitabine; 3TC, lamivudine; ABC, abacavir; TDF, tenofovir; FTC, emtricitabine; EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; DRV, darunavir; LPV, lopinavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; RTV, ritonavir at therapeutic dose; /r, ritonavir at pharmacokinetic boosting dose; RAL, raltegravir; COX, cytochrome c oxidase; FGF-21, fibroblast growth factor 21; NA, not available).

FGF-21 determination
--------------------

Serum FGF-21 levels were determined by quantitative ELISA (BioVendor, Brno, Czech Republic), performed in triplicate, and normalised by log~10~ transformation. A serum FGF-21 level of \<200 pg/ml was considered as normal in keeping with recent data \[[@B18]\]. Statistical analyses were performed in SPSS 19, using student's t-test to compare binary variables and Pearson's correlation coefficient (r) to examine the relationship between log~10~ serum FGF-21 levels and continuous variables. Twenty-one of 32 subjects (66%) had serum FGF-21 levels greater than the normal range, with four being very elevated (\>800 pg/ml). On univariate analysis, serum FGF-21 levels were positively correlated with current CD4 lymphocyte count (r = 0.36, p = 0.042), but more strongly correlated with total CD4 cell count gain since initiation of anti-retroviral therapy (current minus nadir) (r = 0.45, p = 0.016) (Figure [1](#F1){ref-type="fig"}). In addition, plasma glucose levels correlated with serum FGF-21 levels, although this did not quite reach statistical significance (r = 0.34, p = 0.06, Figure [2](#F2){ref-type="fig"}), whereas as serum lipids and liver function did not. No other demographic or treatment variables were significantly associated with serum FGF-21 levels, including the nature of current or prior anti-retroviral therapy (Table [2](#T2){ref-type="table"}). FGF-21 levels did not differ significantly between patients with or without clinical lipodystrophy syndrome. Only CD4 lymphocyte count gain was independently associated with serum FGF-21 levels on multivariate linear regression analysis (p = 0.016).

![**Correlation of serum FGF-21 levels with immune reconstitution.** Correlation of log~10~ serum FGF-21 (fibroblast growth factor 21) levels in HIV-infected subjects and CD4 lymphocyte count gain on treatment (current minus nadir) (r = 0.45, p = 0.016). (\* Serum FGF-21 \>1920 pg/ml, the upper limit of quantitation of the assay).](1742-6405-10-27-1){#F1}

![**Correlation of serum FGF-21 levels with plasma glucose.** Correlation of log~10~ serum FGF-21 (fibroblast growth factor 21) levels in HIV-infected subjects and random plasma glucose concentration (r = 0.34, p = 0.06). (\* Serum FGF-21 \>1920 pg/ml, the upper limit of quantitation of the assay).](1742-6405-10-27-2){#F2}

###### 

Associations of serum FGF-21 levels

                 **(a)**                                                                          
  ------------------------------------- ----------------------- --------------------------------- -------------
                 Gender                        Male (26)                   2.39 (0.40)                   
                                              Female (6)                   2.46 (0.48)                0.71
                Ethnicity                   Caucasian (27)                 2.44 (0.33)                   
                                           Black African (5)               2.21 (0.72)                0.27
               Current ART                      PI (7)                     2.29 (0.26)                   
                                              No PI (25)                   2.43 (0.44)                0.43
              Lifetime ART                    d-drugs (8)                  2.38 (0.26)                   
                                            No d-drugs (24)                2.41 (0.45)                0.86
                                               AZT (23)                    2.44 (0.42)                   
                                              No AZT (9)                   2.30 (0.39)                0.41
              Lipodystrophy                    Yes (10)                    2.50 (0.27)                   
                                                No (22)                    2.36 (0.46)                0.39
         Lipid-lowering therapy                 Yes (8)                    2.32 (0.52)                   
                                                No (24)                    2.43 (0.38)                0.53
                 **(b)**                                                                          
              **Variable**                                       **Correlation coefficient (r)**   **p value**
                   Age                                                        −0.07                   0.69
   Duration of diagnosed HIV infection                                        −0.08                   0.67
        Duration of lifetime ART                 Total                        0.12                    0.50
                                                d-drug                        0.01                    0.97
                                                  AZT                         0.13                    0.47
          CD4 lymphocyte count                   Nadir                        −0.29                   0.14
                                                Current                     **0.36**                **0.042**
             CD4 count gain              (Current minus nadir)              **0.45**                **0.016**
                Serum ALT                                                     0.27                    0.14
             Plasma glucose                                                 **0.34**                **0.06**
              Serum lipids                 Total cholesterol                  −0.03                   0.87
                                            HDL cholesterol                   0.02                    0.90
                                          Non-HDL cholesterol                 −0.06                   0.75
      Mitochondrial histochemistry       COX defect (log~10~)                 −0.02                   0.91

\(a\) binary variables; (b) continuous variables. (PI, protease inhibitor; AZT, zidovudine; d-drug, dideoxynucleoside analogue; ART, anti-retroviral therapy; ALT, alanine transaminase; HDL, high density lipoprotein).

Bold type indicates statistically significant associations.

Skeletal muscle mitochondrial histochemistry
--------------------------------------------

COX histochemistry was performed on cryo-sections obtained from lower limb skeletal muscle biopsies on 31 of the 32 subjects (biopsy data for one subject was not analysable). Results of 22 of these biopsies have been reported in our previous work \[[@B8]\], whereas the remaining 9 have not. COX contains respiratory chain subunits encoded by the mitochondrial genome, and fibres stain brown (positive) in the presence of intact respiratory chain activity (Figure [3](#F3){ref-type="fig"}). Proportional COX defect was determined by counting ≥500 fibres per biopsy, and normalised by log~10~ transformation. There was no correlation between serum FGF-21 levels and percentage COX defects on biopsy (r = −0.02, p = 0.9, Figure [4](#F4){ref-type="fig"}).

![**COX histochemistry.** Example of mitochondrial COX/SDH (cytochrome c oxidase/succinate dehydrogenase) histochemistry on lower limb skeletal muscle biopsy of an anti-retroviral treated HIV-infected patient. Normal (COX positive) fibres stain brown, whereas COX deficient fibres counterstain blue due to preserved SDH activity.](1742-6405-10-27-3){#F3}

![**Correlation of serum FGF-21 levels and mitochondrial defects.** Correlation of log~10~ serum FGF-21 (fibroblast growth factor 21) levels in HIV-infected subjects and percentage COX (cytochrome *c* oxidase) defect on lower limb skeletal muscle biopsy (r = -0.02, p = 0.9). (\* Serum FGF-21 \>1920 pg/ml, the upper limit of quantitation of the assay).](1742-6405-10-27-4){#F4}

Discussion
----------

We have shown that serum FGF-21 levels are frequently elevated in contemporary anti-retroviral treated HIV-infected patients, but do not correlate with the severity of muscle mitochondrial (COX) defect. In contrast, a previous study has shown a very strong correlation between these parameters in patients with inherited mitochondrial disorders \[[@B18]\]. Ours is the first study to attempt to link serum FGF-21 levels with biopsy-proven mitochondrial defects in HIV-infected patients. What is the reason for this apparent discrepancy in findings? Firstly, the prior study demonstrating serum FGF-21 elevation in mitochondrial disease included a large number of patients with childhood-onset disease. Such patients typically have very severe muscle COX defects (affecting up to \~60% of fibres). In contrast, patients with late-onset inherited mitochondrial disorders typically have more modest COX defects, comparable with those seen in our HIV-infected patients (up to \~10% of fibres). The fact that some patients in our study with a biopsy COX defect of \>5% of fibres had relatively normal FGF-21 levels suggests that this serum measure is not particularly sensitive for mild to moderate muscle mitochondrial defects. Secondly, the markedly abnormal serum FGF-21 levels seen in some patients with no significant COX defect suggest a non-mitochondrial origin, as has been observed in other metabolic disorders \[[@B21]-[@B23]\]. In the only previous study of FGF-21 levels in HIV infection, the authors found associations of FGF-21 levels with obesity, glycaemia, dyslipidaemia and liver dysfunction, in line with literature from HIV-uninfected patients \[[@B24]\]. In our study, we specifically excluded diabetic and obese subjects (as we wished to maximise the likelihood of detecting any association with NRTI-induced mitochondrial dysfunction). Interestingly however, the strongest predictor of serum FGF-21 levels seen in our study was a novel association with total CD4 lymphocyte count gain. This is an intriguing finding. It is plausible that patients who have low nadir CD4 lymphocyte counts may experience more profound metabolic changes as they undergo immune reconstitution on anti-retroviral therapy, switching from a catabolic state to an excessively anabolic state associated with a 'return to health'. This association with CD4 count gain should be further explored by longitudinal study.

In conclusion, serum FGF-21 levels do not appear to be a sensitive or specific marker of muscle mitochondrial dysfunction in contemporary anti-retroviral treated patients. Nevertheless they are commonly elevated in association with immune recovery. As serum FGF-21 levels in the HIV-uninfected population are elevated in conditions associated with increased cardiovascular risk, it is very plausible that serum FGF-21 elevation in anti-retroviral treated HIV infection may also be a marker of an adverse metabolic risk in this patient group. Given the known increase in cardiovascular disease in anti-retroviral treated patients \[[@B25]\], the prognostic significance of our findings merits further research.
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